BIONi010-C-10

human

episomal

age (N/A)

EBiSC^™

male

adherent (pluripotent)

cell culture | stem cell: suitable

none

dry ice

−196℃

Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to an embryonic stem cell–like state. The cells can replicate indefinitely or, under controlled conditions, can be differentiated into any other cell type such as nerve, heart or liver cells. Medical researchers are able to use iPS cells to test how different patients might respond to new drugs or to analyse how genetic diseases develop.

The EBiSC stem cell bank is a collection of human iPS cells available to academic and commercial researchers for use in disease modelling and other forms of stem cell research. The initial collection has been generated from a wide range of donors representing specific disease backgrounds and healthy controls. EBiSC has established many routine procedures for collecting, expanding and characterizing human iPS cell lines. The stem cell bank includes iPSC cell lines derived from neurodegenerative diseases (Alzheimer′s Disease, Parkinson′s Disease, Dementia, Motor Neuron Disease (ALS) - and Huntington′s Disease), eye and heart diseases, and lines from healthy control donors for age and sex matching.

Depositor
Bioneer

Derivation
Primary cell type: -
Reprogramming method
Vector type: Non-integrating
Vector: Episomal
Is the reprogramming vector detectable: No

Xeno free conditions: no
Derived under gmp: no
Available as clinical grade: no

Characterization
Microbiology / Virus Screening
HIV 1: -
HIV 2: -
Hepatitis B: -
Hepatitis C: -
Mycoplasma: Negative

Genotyping
Karyotyping
Passage number: P11
Cell line karyotype: 46, XY
Karyotyping method: G-Banding
Image / Result

Genetic Modification
Disease/phenotype related modifications
Disease: MODY
Type of modification: Isogenic
Gene: HNF1A
Chromosome location: 12q24.31
Nucleotide sequence HGSV: NM_000545.6:c.(c.872dup)
Protein sequence HGSV: NP_000536.5:p.(P291fsinsC)
Zygosity: Heterozygous
Target locus modification: Mutated
Description: An additional cytocine has been introduced by CRISPR-Cas9 into a poly-C tract in Exon 4 of HNF1A resulting in a out of frame mutation. It is likely that the other allele has also been targeted, since western blotting did not show any HNF1A protein in Pancreatic progenitor cells compared to the control line BIONi010-C.

• Additional Cell Line Info
• EBiSC Access Use Agreement (EAUA)
• Cell Line Information Pack (CLIP)

Note: EAUA and CLIP must be completed before order fulfillment

Surface coating: Matrigel^®/Geltrex^®
Passage method: Enzyme-free cell dissociation / EDTA
O₂ concentration: 20%
CO₂ concentration: 5%
Culture medium: mTeSR^® 1
Passage Number banked (pre-EBiSC): 12
No. Vials banked (pre-EBiSC): 4

EBiSC is a trademark of Fraunhofer-Gesellschaft
GELTREX is a registered trademark of Life Technologies Corporation
Matrigel is a registered trademark of Corning, Inc.
mTeSR is a registered trademark of WiCell Research Institute, Inc.

6.2 - Infectious substances

WGK 3